The general manager of the Bila Solar unit in Indianapolis, said legislation could impede plans to expand the company’s solar ...

President Trump has threatened to impose pharma tariffs to encourage investment in U.S. manufacturing, but experts say there could be unintended consequences.

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Sitting at her perch from the “Massachusetts Pavilion,” Gov. Maura Healey briefly gestured Tuesday to nearby competitors with flashy booths set up at the BIO International Convention, ...

Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the ...